1. Novo Nordisk fellowship program

2. Novo Nordisk at a glance
Introduction to the company
Novo Nordisk is a global healthcare company
with 90 years of innovation and leadership within:
• diabetes care
• insulin
• injection devices
Thanks to dedicated research into proteins,
Novo Nordisk also holds leading positions within:
• haemostasis management
• growth hormone therapy
• hormone replacement therapy

4. Novo Nordisk Worldwide: > 33,000 employees
Production sites
R&D facilities
Clinical development centres
Affiliates
Representative offices
Regional and business area offices

5. Seattle
Beijing
Denmark
Bangalore
Princeton
R&D locations
• Copenhagen, Denmark
• Beijing, China
• Seattle, WA, USA
• Princeton, NJ, USA
• Bangalore, India
Clinical Development centres
• Zürich, Switzerland
• Beijing, China
• Princeton, NJ, USA
• Tokyo, Japan
>3800 staff
today, 5000
staff in 2020
Global
R&D

6. The ability to attract talent in Denmark is key to us
81
3898
154
194
27
R&D 4354
Employees in R&D 01-Mar-2013

7. Additional Novo Nordisk R&D facts
• > DKK 10 billion R&D investment
• Ranked 4th
out of 20 international pharmaceutical and biotech
companies listed as best employers by Science Magazine
• 778 scientific publication in 2010-11 (2010 h-index: 26)
• 25 PhD and 6 post docs supported through the LIFEPHARM PhD
school at University of Copenhagen focussing on pharmacology.
• ~ 100 PhD/PostDoc science students from Europe, North
America and Asia
• Top rating in Dow Jones Sustainability Index for the last ten
years

8. 8Industry talent requirements and challenges
We rely on excellent talent within all our competency
areas to sustain growth
E.coli
Yeast
Mammalian cells
Prefilled pens
Durable pens
Oral delivery
Liquid delivery
Sustained release
Subc. delivery
Amino acid substitution
Acylation
Medical insight
Trial design
Execution
Therapy area expertise
Modification

9. Our core beliefs
9Industry talent requirements and challenges
INNOVATION
&
GROWTH
INNOVATION
&
GROWTH
Talents
DiversityPerformance

10. Fellowship Programmes
Talent
Attraction
Support of
Education
System
Long term
Relations
Knowledge
Transfer

12. STAR PostDoc Fellows 2013
Active and completed 1998 – 30 June 2013
Burnham Institut
Medical Research
Clinical Medical Regulatory OfficesR&D locations
Berkley
McGill
University
Loyola
Consiglio Nazionale
delle Ricerche
Chapel Hill
University
Princeton
San Francisco
University
Sigma Aldrich
(SAFC)
Stanford
University
Toronto
University
Washington
University
Vrije
University
Harvard
Dublin
University
Geneva
University
Institute for
Biomedicine and
Health Science
Justus-Liebig
University
Karolinska
Institutet
Kings
College
Linköping
University
Lund
University
Manchester
University
Martin Luther
University
Nottingham
University
Santiago de
Compostela
University
Uppsala
University
The Hebrew
University-Hadassah
Setsunan University,
Osaka, Japan
Tokyo University
Fudan University

13. Novo Nordisk STAR fellows
Professional Qualifications
• Strong competences from active research environments
• International experience and networks
• Good publications (and PhD thesis) and/or patent applications
• Skills in new technologies
• High personal ambitions

14. STAR fellowship postgraduate training 2013

15. STAR Symposium activities

16. LIFEPHARM
The Novo Nordisk–LIFE In Vivo Pharmacology Centre
Public – Private – Partnership
Established 1/9/2010
Aim
•Reinforcement of section of pharmacology and toxicology @ LIFE
•Continued output of PhD candidates with ’in vivo’ expertise
•Ensure the continuation of the In Vivo PhD Program
Funding
•9.1 M Euro 2010-2015
• 6 mill Euros from Novo Nordisk A/S
• 3.1 mill Euros from LIFE
Resources
•24 PhD scholarships
•5 Postdoctoral fellowships (2 years each)
•Professorship in clinical pharmacology & toxicology
Framework for an InnoLIFE
PhD programme
18/05/14

17. • Novo Science Ambassadors
• Novo Nordisk and Novozymes have established a team of young Novo
Scholarship recipients in order to stimulate the interest for natural and
medical science in the schools.
• The ambassadors’ lectures are free and can be booked at www.formidling.dk
Novo Science Ambasadors
17Presentation title Date

18. Recently: Elite Post Doc programme
with Oxford University
• A recruitment platform for international top
talents within diabetes research
• An international platform for branding NN as
a top-science employer
• A platform for on-campus recruitment
activities
• A platform for expanding scientific
collaboration between NN and UO
• 3-year fellowships fully funded by Novo
Nordisk
Objectives Scope
18November 2013

19. Recently: Elite Post Doc programme
with Stanford University
• A recruitment platform for international top
talents within immunology research
• An international platform for branding NN as
a top-science employer
• A platform for on-campus recruitment
activities
• A platform for expanding scientific
collaboration between NN and Stanford
• 2 to 3-year fellowships fully funded by Novo
Nordisk
Objectives Scope
19November 2013
Institute for Immunity,
Transplantion and Infection

20. Slide no 20 • •
Evaluation of Early innovation/research
New metrics for evaluation of the innovation
outcome such as:
• networks created,
• access to novel technology & implementation
• access to important know-how & implementation
on top of the classical metrics such as:
• publications,
• patent applications filed,
• science citations etc.

21. Novo Nordisk R&D career paths
• To clarify
development
opportunities
• To specify
qualifiers for
different job
types and
levels

22. More information at novonordisk.com/careers